Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice
Trastuzumab prolongs progression-free and overall survival in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer. However, trastuzumab treatment is hampered by cardiotoxicity, defined as a left ventricular ejection fraction (LVEF) decline with a reported incidence r...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-08-01
|
| Series: | Breast |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977620300928 |
| _version_ | 1819073665834156032 |
|---|---|
| author | Nathalie I. Bouwer Agnes Jager Crista Liesting Marcel J.M. Kofflard Jasper J. Brugts Jos J.E.M. Kitzen Eric Boersma Mark-David Levin |
| author_facet | Nathalie I. Bouwer Agnes Jager Crista Liesting Marcel J.M. Kofflard Jasper J. Brugts Jos J.E.M. Kitzen Eric Boersma Mark-David Levin |
| author_sort | Nathalie I. Bouwer |
| collection | DOAJ |
| description | Trastuzumab prolongs progression-free and overall survival in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer. However, trastuzumab treatment is hampered by cardiotoxicity, defined as a left ventricular ejection fraction (LVEF) decline with a reported incidence ranging from 3 to 27% depending on variable factors. Early identification of patients at increased risk of trastuzumab-induced myocardial damage is of great importance to prevent deterioration to irreversible cardiotoxicity. Although current cardiac monitoring with multi gated acquisition (MUGA) scanning and/or conventional 2D-echocardiography (2DE) have a high availability, their reproducibility are modest, and more sensitive and reliable techniques are needed such as 3D-echocardiography (3DE) and speckle tracking echocardiography (STE). But which other diagnostic imaging modalities are available for patients before and during trastuzumab treatment? In addition, what is the optimal frequency and duration of cardiac monitoring? At last, which biomarker monitoring strategies are currently available for the identification of cardiotoxicity in patients treated with trastuzumab? |
| first_indexed | 2024-12-21T17:57:14Z |
| format | Article |
| id | doaj.art-5d775c2192d24d79bd7fdf7a7678540f |
| institution | Directory Open Access Journal |
| issn | 1532-3080 |
| language | English |
| last_indexed | 2024-12-21T17:57:14Z |
| publishDate | 2020-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Breast |
| spelling | doaj.art-5d775c2192d24d79bd7fdf7a7678540f2022-12-21T18:55:10ZengElsevierBreast1532-30802020-08-01523344Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practiceNathalie I. Bouwer0Agnes Jager1Crista Liesting2Marcel J.M. Kofflard3Jasper J. Brugts4Jos J.E.M. Kitzen5Eric Boersma6Mark-David Levin7Department of Cardiology, Albert Schweitzer Hospital, Albert Schweitzerplaats 25, 3300 AK, Dordrecht, the Netherlands; Department of Internal Medicine, Albert Schweitzer Hospital, Albert Schweitzerplaats 25, 3300 AK, Dordrecht, the NetherlandsDepartment of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3000 CA, Rotterdam, the NetherlandsDepartment of Cardiology, Albert Schweitzer Hospital, Albert Schweitzerplaats 25, 3300 AK, Dordrecht, the NetherlandsDepartment of Cardiology, Albert Schweitzer Hospital, Albert Schweitzerplaats 25, 3300 AK, Dordrecht, the NetherlandsDepartment of Cardiology, Erasmus MC Thoraxcenter, Dr. Molewaterplein 40, 3000 CA, Rotterdam, the NetherlandsDepartment of Internal Medicine, Albert Schweitzer Hospital, Albert Schweitzerplaats 25, 3300 AK, Dordrecht, the NetherlandsDepartment of Cardiology, Erasmus MC Thoraxcenter, Dr. Molewaterplein 40, 3000 CA, Rotterdam, the NetherlandsDepartment of Internal Medicine, Albert Schweitzer Hospital, Albert Schweitzerplaats 25, 3300 AK, Dordrecht, the Netherlands; Corresponding author.Trastuzumab prolongs progression-free and overall survival in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer. However, trastuzumab treatment is hampered by cardiotoxicity, defined as a left ventricular ejection fraction (LVEF) decline with a reported incidence ranging from 3 to 27% depending on variable factors. Early identification of patients at increased risk of trastuzumab-induced myocardial damage is of great importance to prevent deterioration to irreversible cardiotoxicity. Although current cardiac monitoring with multi gated acquisition (MUGA) scanning and/or conventional 2D-echocardiography (2DE) have a high availability, their reproducibility are modest, and more sensitive and reliable techniques are needed such as 3D-echocardiography (3DE) and speckle tracking echocardiography (STE). But which other diagnostic imaging modalities are available for patients before and during trastuzumab treatment? In addition, what is the optimal frequency and duration of cardiac monitoring? At last, which biomarker monitoring strategies are currently available for the identification of cardiotoxicity in patients treated with trastuzumab?http://www.sciencedirect.com/science/article/pii/S0960977620300928TrastuzumabCardiotoxicityCardiac monitoringBiomarkersSpeckle tracking echocardiography |
| spellingShingle | Nathalie I. Bouwer Agnes Jager Crista Liesting Marcel J.M. Kofflard Jasper J. Brugts Jos J.E.M. Kitzen Eric Boersma Mark-David Levin Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice Breast Trastuzumab Cardiotoxicity Cardiac monitoring Biomarkers Speckle tracking echocardiography |
| title | Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice |
| title_full | Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice |
| title_fullStr | Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice |
| title_full_unstemmed | Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice |
| title_short | Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice |
| title_sort | cardiac monitoring in her2 positive patients on trastuzumab treatment a review and implications for clinical practice |
| topic | Trastuzumab Cardiotoxicity Cardiac monitoring Biomarkers Speckle tracking echocardiography |
| url | http://www.sciencedirect.com/science/article/pii/S0960977620300928 |
| work_keys_str_mv | AT nathalieibouwer cardiacmonitoringinher2positivepatientsontrastuzumabtreatmentareviewandimplicationsforclinicalpractice AT agnesjager cardiacmonitoringinher2positivepatientsontrastuzumabtreatmentareviewandimplicationsforclinicalpractice AT cristaliesting cardiacmonitoringinher2positivepatientsontrastuzumabtreatmentareviewandimplicationsforclinicalpractice AT marceljmkofflard cardiacmonitoringinher2positivepatientsontrastuzumabtreatmentareviewandimplicationsforclinicalpractice AT jasperjbrugts cardiacmonitoringinher2positivepatientsontrastuzumabtreatmentareviewandimplicationsforclinicalpractice AT josjemkitzen cardiacmonitoringinher2positivepatientsontrastuzumabtreatmentareviewandimplicationsforclinicalpractice AT ericboersma cardiacmonitoringinher2positivepatientsontrastuzumabtreatmentareviewandimplicationsforclinicalpractice AT markdavidlevin cardiacmonitoringinher2positivepatientsontrastuzumabtreatmentareviewandimplicationsforclinicalpractice |